Truscreen Group Ltd
NZX:TRU
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.015
0.028
|
| Price Target |
|
We'll email you a reminder when the closing price reaches NZD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Truscreen Group Ltd
Truscreen Group Ltd
Cost of Revenue
Truscreen Group Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Truscreen Group Ltd
NZX:TRU
|
Cost of Revenue
-NZ$1.4m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
Fisher & Paykel Healthcare Corporation Ltd
NZX:FPH
|
Cost of Revenue
-NZ$698.4m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
Truscreen Group Ltd
Glance View
TruScreen Group Ltd. engages in the development, manufacture, and sale of cancer detection device and systems. The firm is engaged in the business of the development, manufacturing and sale of cancer detection devices and systems. Its cervical cancer screening device offers technology in cervical screening, providing detection of precancerous and cancerous cervical cells to help improve the health and well-being of women worldwide. Its real-time cervical cancer technology utilizes a digital wand, which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated algorithm framework is utilized to detect pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue. The product offers an approach to cervical screening, resolving ongoing issues with Pap smear (Pap tests), including failed samples, patient follow-up, patient discomfort and the need for supporting laboratory infrastructure.
See Also
What is Truscreen Group Ltd's Cost of Revenue?
Cost of Revenue
-1.4m
NZD
Based on the financial report for Mar 31, 2024, Truscreen Group Ltd's Cost of Revenue amounts to -1.4m NZD.
What is Truscreen Group Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-1%
Over the last year, the Cost of Revenue growth was -18%. The average annual Cost of Revenue growth rates for Truscreen Group Ltd have been -25% over the past three years , -1% over the past five years .
You don't have any saved screeners yet
